Prognostic factors in patients with primary operable breast cancer (cT1-2N0-1M0) after reconstructive plastic surgery with single-stage reconstruction using endoprosthesis

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0001-9195-4181

Zikiryakhodzhaev A.D.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia;
Peoples’ Friendship University of Russia

SPIN RSCI: 8421-0364
Scopus AuthorID: 57220129122
ORCID: 0000-0001-7141-2502

Usov F.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0001-9510-1434

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0002-4880-0213

Gerasimov A.N.

Central Research Institute for Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

ORCID: 0000-0003-4549-7172

Duadze I.S.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0002-9577-584X

Dzhabrailova D.Sh.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Laberko D.A.

People’s Friendship University of Russia

Batov M.A.

National Medical Research Radiological Centre

Prognostic factors in patients with primary operable breast cancer (cT1-2N0-1M0) after reconstructive plastic surgery with single-stage reconstruction using endoprosthesis

Authors:

Bagdasarova D.V., Zikiryakhodzhaev A.D., Usov F.N., Khmelevsky E.V., Gerasimov A.N., Duadze I.S., Dzhabrailova D.Sh., Laberko D.A., Batov M.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(4): 34‑38

DOI: 10.17116/onkolog20221104134

Downloaded: 21

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bagdasarova DV, Zikiryakhodzhaev AD, Usov FN, et al. . Prognostic factors in patients with primary operable breast cancer (cT1-2N0-1M0) after reconstructive plastic surgery with single-stage reconstruction using endoprosthesis. P.A. Herzen Journal of Oncology. 2022;11(4):34‑38. (In Russ.)
https://doi.org/10.17116/onkolog20221104134

Close metadata

OBJECTIVE

To identify poor prognostic factors and event-free survival rates in patients with primary operable breast cancer (BC) after single-stage reconstruction.

Subjects and methods. The investigation analyzed the data of 203 patients with BC who had undergone skin-sparing/subcutaneous mastectomy (SSME/SCME) with single-stage reconstruction using a silicone endoprosthesis within combined or combination treatment between 2008 to March 2018. The patients’ mean age at the time of surgery was 45.08±0.65 years (range 18—75 years). The median follow-up was 51 months (95% CI: 49 to 53 months); the mean follow-up was 60.3±1.9 months. SCME with single-stage reconstruction with a silicone endoprosthesis was performed in 71.4% of patients.

RESULTS

The cumulative relapse-free survival at 3 and 5 years was 100%; that at 10 years was 92.6% (95% CI: 81.9—100%). The mean time to progression was 30.9 months. The distant metastasis-free survival at 3 years was 97% (95% CI: 94.7—99.4%); and that at 10 years was 91.6% (95% CI: 86.7—96.6%). The 10-year tumor-specific survival in the entire patient group was 99.3%. The presence of lymphovascular invasion (p=0.048) and regional lymph node metastasis (p=0.008) was associated with worse event-free survival.

CONCLUSION

SSME/SCME with single-stage reconstruction using a silicone endoprosthesis is a safe surgical option for patients with BC. The risk of local recurrence and progression remains high within the next 5 years after the treatment and stable within the next 10 years.

Keywords:

breast cancer

mastectomy

single-stage breast reconstruction

radiotherapy

implant

Authors:

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0001-9195-4181

Zikiryakhodzhaev A.D.

SPIN RSCI: 8421-0364
Scopus AuthorID: 57220129122
ORCID: 0000-0001-7141-2502

Usov F.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0001-9510-1434

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0002-4880-0213

Gerasimov A.N.

Central Research Institute for Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

ORCID: 0000-0003-4549-7172

Duadze I.S.

ORCID: 0000-0002-9577-584X

Dzhabrailova D.Sh.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Laberko D.A.

People’s Friendship University of Russia

Batov M.A.

National Medical Research Radiological Centre

Received:

22.04.2022

Accepted:

27.04.2022

List of references:

Kaprin AD, Starinskii VV, Shakhzadova AO. Zlokachestvennye novoobrazovaniya v Rossii v 2019 (zabolevaemost’ i smertnost’). M.: MNIOI imeni P.A. Gertsena — filial FGBU «NMITs radiologii» Ministerstva zdravookhraneniya Rossiiskoi Federatsii; 2020. (In Russ.).
Galimberti V, Vicini E, Corso G, Morigi C, Fontana S, Sacchini V, Veronesi P. Nipple-sparing and skin-sparing mastectomy: review of aims, oncological safety and contraindications. Breast. 2017;34(suppl 1):82-84. https://doi.org/10.1016/j.breast.2017.06.034
Bernier J. Postoperative radiotherapy after nipple- or skin-sparing mastectomy: a review of recent institutional and pooled data. Ecancermedicalscience. 2018;12:834. https://doi.org/10.3332/ecancer.2018.834
Harcourt D, Rumsey N. Psychological aspects of breast reconstruction: a review of the literature. J Adv Nurs. 2001;35(4):477-487. https://doi.org/10.1046/j.1365-2648.2001.01865.x
Meretoja TJ, Rasia S, von Smitten KA, Asko-Seljavaara SL, Kuokkanen HO, Jahkola TA. Late results of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg. 2007;94(10):1220-1225. https://doi.org/10.1002/bjs.5815
Zikiryakhodzhaev AD, Rasskazova EA. Retsidivy raka molochnoi zhelezy posle podkozhnykh radikal’nykh mastektomii s odnomomentnoi rekonstruktsiei. Issledovaniya i praktika v meditsine. 2014;1(1):24-28. (In Russ.). https://doi.org/10.17709/2409-2231-2014-1-1-24-28
Zikiryakhodzhaev AD, Rasskazova EA, Khakimova ShG. Onkologicheskaya bezopasnost’ radikal’nykh podkozhnykh/kozhesokhrannykh mastektomii s odnomomentnoi rekonstruktsiei pri rake. Voprosy onkologii. 2019;65(6):832-837. (In Russ.). https://doi.org/10.37469/0507-3758-2019-65-6-832-837
Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg. 2010;251(4):632-639. https://doi.org/10.1097/SLA.0b013e3181d35bf8
Santoro S, Loreti A, Cavaliere F, Costarelli L, La Pinta M, Manna E, Mauri M, Scavina P, Santini E, De Paula U, Toto V, Fortunato L. Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy. Breast. 2015;24(5):661-666. https://doi.org/10.1016/j.breast.2015.08.001
Galimberti V, Morigi C, Bagnardi V, Corso G, Vicini E, Fontana SKR, Naninato P, Ratini S, Magnoni F, Toesca A, et al. Oncological outcomes of nipple-sparing mastectomy: a single-center experience of 1989 patients. Ann Surg Oncol. 2018;25(13):3849-3857. https://doi.org/10.1245/s10434-018-6759-0
NCCN clinical practice guidelines in oncology: breast cancer, version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Close metadata